This resulted in compound 6, a fast and potent dual degrader of SMARCA2/4 (SMARCA2 DC50 = 2 nM, Dmax = 77%; SMARCA4 DC50 = 5 nM, Dmax = 86%, in RKO cells after 4 h) (Fig. 2c, Supplementary Data 3) that displayed the expected anti-proliferative effect (EC50 = 2 nM, Supplementary Data 4) in a SMARCA4-deficient lung cancer cell line, NCI-H1568. This evidence concerns the gene SMARCA2 and lung carcinoma.